SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...

Art Pappas to moderate panel, "Accessing Capital through Risk-Sharing Models between Early-Stage Companies and Contract Research Organizations" at BIO 2010 in Chicago, IL
News | 05. 05. 2010